Search for: "CARR v. STATE" Results 281 - 300 of 837
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
19 Jul 2017, 4:30 am by koherston
When Child was 17 years old, the State petitioned to establish paternity and require the father to provide health insurance for Child. [read post]
11 Jul 2017, 12:55 pm
On June 15, 2017, the Ohio Supreme Court issued its decision in Dialysis Ctrs. of Dayton, L.L.C. v. [read post]
10 Jul 2017, 4:00 am
On June 15, 2017, the Ohio Supreme Court issued its decision in Dialysis Ctrs. of Dayton, L.L.C. v. [read post]
5 Jul 2017, 11:34 am
Patrick Huston, which “organizes, analyzes and synthesizes all of the 48 UTSA-adopting states’ published court opinions (state and federal). [read post]
12 Jun 2017, 4:00 am
By: Connie CarrA recent decision by the Ohio Supreme Court (the “Court”) highlights once again the importance of clearly stating in your contract what you mean or a court will decide for you.Bohlen v. [read post]
9 Jun 2017, 12:53 am
Chugai Pharmaceutical v UCB [2017] EWHC 1216 (Pat) is a decision of Mr Justice Henry Carr (correctly named in full to avoid any possible confusion with Mrs Justice (Sue) Carr), which is given in admirably clear terms despite its complex subject matter. [read post]
7 Jun 2017, 5:54 pm
 Yesterday morning's second instalment in the Unwired Planet v Huawei FRAND dispute was a page turner introducing a new type of IP injunction - a FRAND injunction. [read post]
5 May 2017, 11:37 am by Patricia Salkin
Carr (collectively, Wooster petitioners) and Buffalo Niagara Riverkeeper, Inc. commenced these CPLR article 78 proceedings seeking to annul the negative declaration issued by respondent City of Buffalo Planning Board under the State Environmental Quality Review Act (SEQRA) with respect to the proposed construction of Queen City Landing in Buffalo’s Outer Harbor area. [read post]
21 Apr 2017, 6:59 am by Brian Cordery
Penny sketched out the facts of the FKB v AbbVie litigation in the UK and the finding of Henry Carr J that it was appropriate to grant declarations that a dosage regime for a biosimilar product would have been anticipated or obvious at the priority date of a granted patent in the circumstances. [read post]